Are two antiandrogens better than one in metastatic prostate cancer?
Final results of the ACIS study in patients with castration-resistant disease show a benefit in radiographic progression-free survival
Apalutamide in addition to standard care for metastatic castration-resistant prostate cancer (mCRPC) leads to better radiographic progression-free survival, a trial shows.
Final results from the international phase III trial also suggest that double antiandrogen therapy is tolerated as well as abiraterone acetate plus prednisone alone, the researchers say.
